The use of angiotensin II in distributive shock

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Chawla, Lakhmir S ^a   Busse, Laurence W ^b   Brasha Mitchell, Ermira ^a   Alotaibi, Ziyad ^c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c Prince Sultan Military Medical City   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPERTENSIVE AGENT; NORADRENALIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTERIAL PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; LUNG ENDOTHELIUM; NOTE; PRIORITY JOURNAL; SHOCK; HUMAN; PATHOPHYSIOLOGY;

ANGIOTENSIN II; HUMANS; SHOCK;

EID: 84973340624     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-016-1306-5     Document Type: Note

References (12)

1. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25(8):1279-82.
2. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-87.
3. Derrick JR, Anderson JR, Roland BJ. Adjunctive use of a biologic pressor agent, angiotensin, in management of shock. Circulation. 1962;25:263-7.
4. Kimmoun A, Levy B. Angiotensin II: a new approach for refractory shock management? Crit Care. 2014;18(6):694.
5. Cohn JN, Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44:1494-504.
6. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.
7. Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation. 1999;99(12):1593-9.
8. Orfanos SE, Chen XL, Ryan JW, Chung AY, Burch SE, Catravas JD. Assay of pulmonary microvascular endothelial angiotensin-converting enzyme in vivo: comparison of three probes. Toxicol Appl Pharmacol. 1994;124(1):99-111.
9. Cziraki A, Horvath I, Rubin JW, Theodorakis M, Catravas JD. Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man. Gen Pharmacol. 2000;35(4):213-8.
10. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-49.
11. Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation. 2000;102(16):2011-8.
12. Correa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med. 2014;42(8):e550-9.